Targeting macula densa cells as a new therapeutic approach for kidney disease
There is no specific cure for chronic kidney disease (CKD), which affects one in every ten adults. The unmet medical need has created significant interest in regenerative therapeutic approaches. Described herein is a radically new and innovative therapeutic approach identified by characterizing a novel mechanism of renal tissue repair and its role in glomerular injury. By targeting this mechanism in CKD, significant therapeutic benefit supported by rapid cellular remodeling of kidney tissues, coincident with structural and functional nephron regeneration. Methods and compositions for achieving the described therapeutic approach are fundamentally different from existing strategies.
1. A composition comprising media that was used to culture human macula densa (md) cells and comprising a protein secreted into the media by the human md cells.
2. A method of treating chronic kidney disease comprising administering the composition of claim 1 to a subject in need thereof.
3. The composition of claim 1 , wherein the human and cells are primary cells.
4. The composition of claim 1 , wherein the human md cells are immortalized.
5. The composition of claim 1 , wherein the media is prepared by a method comprising starving the human md cells for about 24 hours; and culturing the human md cells in the media for at least three hours.
6. The composition of claim 5 , wherein the media is a low salt media.
7. The composition of claim 1 , wherein the media is enriched in angiogenic factors, or glomerulotropic factor, or both.
8. The method of claim 2 , wherein the method of treatment comprises:
administering the composition by injection under the renal capsule.
9. The composition of claim 1 , wherein the secreted protein is one or more of CCN family member 1 (CCN1), Pregnancy-associated plasma protein A2 (Pappa-2), nephroblastoma overexpressed (Nov), Vascular endothelial growth factor (VEGF), Bone morphogenetic protein 3 (BMP3), Matrix Metallopeptidase 14 (MMP14), or Growth/differentiation factor 15 (GDF15).
10. The composition of claim 1 , wherein the media further comprises a growth factor.
11. The composition of claim 10 , wherein the growth factor is Nerve growth factor (NGF) or Fibroblast Growth Factor 2 (FGF2).
12. The composition of claim 11 , wherein the secreted protein is one or more of CCN family member 1 (CCN1), Pregnancy-associated plasma protein A2 (Pappa-2), nephroblastoma overexpressed (Nov), Vascular endothelial growth factor (VEGF), Bone morphogenetic protein 3 (BMP3), Matrix Metallopeptidase 14 (MMP14), or Growth/differentiation factor 15 (GDF15).